Clinical features of early recurrent myocardial infarction

Heart and Vessels

Volumn 24, Issue 5, 2009, Pages 347-351

  Sakakura, Kenichi ^a   Kubo, Norifumi ^a   Ako, Junya ^b   Ikeda, Nahoko ^a   Funayama, Hiroshi ^a   Hirahara, Taishi ^a   Wada, Hiroshi ^a   Sugawara, Yoshitaka ^a   Yasu, Takanori ^a   Kawakami, Masanobu ^a   Momomura, Shin Ichi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Myocardial infarction; Recurrence; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; STATIN; TICLOPIDINE; WARFARIN;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; HEART INFARCTION; HOSPITAL CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; PRIORITY JOURNAL; RECURRENT DISEASE; SECONDARY PREVENTION; SMOKING HABIT; STENT THROMBOSIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CHOLESTEROL, HDL; CORONARY THROMBOSIS; FEMALE; HOSPITAL MORTALITY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; SMOKING; TIME FACTORS; TREATMENT FAILURE;

EID: 70349637454     PISSN: 09108327     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00380-008-1133-y     Document Type: Article

References (22)

1. Weinblatt E, Shapiro S, Frank CW, Sager RV (1968) Prognosis of men after first myocardial infarction: Mortality and first recurrence in relation to selected parameters. Am J Public Health Nations Health 58:1329-1347
2. Marcus FI, Cobb LA, Edwards JE, Kuller L, Moss AJ, Bigger JT Jr, Fleiss JL, Rolnitzky L, Serokman R (1988) Mechanism of death and prevalence of myocardial ischemic symptoms in the terminal event after acute myocardial infarction. Am J Cardiol 61:8-15
3. Orn S, Cleland JG, Romo M, Kjekshus J, Dickstein K (2005) Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. Am J Med 118:752-758
4. Lowe GD, Machado SG, Krol WF, Barton BA, Forbes CD (1985) White blood cell count and haematocrit as predictors of coronary recurrence after myocardial infarction. Thromb Haemost 54:700-703
5. Andersen SS, Hansen ML, Gislason GH, Folke F, Schramm TK, Fosbol E, Sorensen R, Rasmussen S, Abildstrom SZ, Madsen M, Kober L, Torp-Pedersen C (2008) Mortality and reinfarction among patients using different beta-blockers for secondary prevention after a myocardial infarction. Cardiology 112:144-150
6. Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Kober L, Madsen M, Torp-Pedersen C (2006) Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 113:2906-2913
7. Kornowski R, Goldbourt U, Zion M, Mandelzweig L, Kaplinsky E, Levo Y, Behar S (1993) Predictors and long-term prognostic significance of recurrent infarction in the year after a first myocardial infarction. SPRINT Study Group. Am J Cardiol 72:883-888
8. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE (2007) Stent thrombosis in randomized clinical trials of drugeluting stents. N Engl J Med 356:1020-1029
9. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW (2007) Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 115:2344-2351
10. Andrikopoulos GK, Richter DJ, Dilaveris PE, Pipilis A, Zaharoulis A, Gialafos JE, Toutouzas PK, Chimonas ET (2001) In-hospital mortality of habitual cigarette smokers after acute myocardial infarction; the "smoker's paradox" in a countrywide study. Eur Heart J 22:776-784
11. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W (2001) Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104:1108-1113
12. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62:707-714
13. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316:823-828
14. Liuzzo G, Biasucci LM, Trotta G, Brugaletta S, Pinnelli M, Digianuario G, Rizzello V, Rebuzzi AG, Rumi C, Maseri A, Crea F (2007) Unusual CD4+ CD28 null T lymphocytes and recurrence of acute coronary events. J Am Coll Cardiol 50:1450-1458
15. Erzen B, Sabovic M, Sebestjen M, Poredos P (2007) Endothelial dysfunction, intima-media thickness, ankle-brachial pressure index, and pulse pressure in young post-myocardial infarction patients with various expressions of classical risk factors. Heart Vessels 22:215-222
16. Noda M, Takagi A, Kuwatsuru R, Mitsuhashi N, Kasanuki H (2008) Prognostic significance of multiple-detector computed tomography in conjunction with TIMI risk score for patients with non-ST elevation acute coronary syndrome. Heart Vessels 23:161-166
17. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL (2006) Late thrombosis of drug-eluting stents: A meta-analysis of randomized clinical trials. Am J Med 119:1056-1061
18. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P (2007) Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet 370:937-948
19. Silva JA, Nunez E, White CJ, Collins TJ, Jenkins JS, Zhang S, Jain SP, Ramee SR (1999) Predictors of stent thrombosis after primary stenting for acute myocardial infarction. Catheter Cardiovasc Interv 47:415-422
20. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K (1996) A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334:1084-1089
21. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE (1998) A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339:1665-1671
22. Kasai T, Miyauchi K, Kajimoto K, Kubota N, Kurata T, Daida H (2008) Influence of diabetes on >10-year outcomes after percutaneous coronary intervention. Heart Vessels 23:149-154